List of Excipients in Branded Drug ERVEBO

ERVEBO Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 22, 2026

ERVEBO is Merck’s live, recombinant vesicular stomatitis virus vaccine for prevention of disease caused by Zaire ebolavirus. Its excipient system is commercially narrow but strategically important because the product depends on frozen storage, rapid deployment, and public-sector procurement. The principal opportunity is not substitution of commodity excipients in the existing product. It is development of excipient-enabled formulations that improve thermal stability, reduce cold-chain cost, extend field usability, or support alternative presentations.

What is ERVEBO and how is it formulated?

ERVEBO contains a genetically modified recombinant vesicular stomatitis virus in which the native VSV glycoprotein is replaced by the Zaire ebolavirus glycoprotein. The product is supplied as a sterile, preservative-free suspension for intramuscular injection.

The U.S. formulation contains:

Component	Function
Recombinant human serum albumin	Stabilizer and protein-protective excipient
Tromethamine	Buffering agent
Sodium chloride	Tonicity adjustment
Water for Injection	Vehicle

The vaccine is supplied in a single-dose 1 mL vial. The U.S. label requires storage at -80°C to -60°C and permits limited periods at higher temperatures under specified conditions. The product must be thawed before administration and cannot be refrozen after thawing.[1]

The excipient architecture is therefore designed around viral-vector stability rather than conventional small-molecule drug dissolution. The relevant technical risks include loss of viral infectivity, aggregation, adsorption to container surfaces, freeze-concentration effects, and damage during repeated temperature excursions.

What excipients are protected by ERVEBO patents?

Public regulatory documents identify the ERVEBO excipients but do not establish that the commercial formulation is protected by a stand-alone excipient patent. The principal intellectual-property value is associated with the recombinant VSV platform, Ebola glycoprotein expression, vaccine composition, production methods, and use against Ebola disease.

A patent analysis should distinguish four layers:

1. The recombinant viral-vector construct.
2. The Ebola glycoprotein sequence and expression system.
3. Manufacturing and purification processes.
4. Stabilized vaccine compositions, containers, and temperature-controlled presentations.

The fourth category is the main area for excipient-related commercial risk. A formulation patent could claim a specific combination of albumin, buffer, salt, pH range, viral concentration, freezing profile, or storage condition. A competitor would not necessarily need to copy the exact ERVEBO excipient formula if it could demonstrate equivalent viral stability using a different stabilizer system.

Recombinant human serum albumin is strategically relevant because it avoids reliance on plasma-derived albumin and can reduce concerns relating to human blood-borne pathogens. Its presence may also create supplier qualification requirements, because a vaccine manufacturer must establish identity, purity, viral safety, residual host-cell controls, and lot-to-lot consistency.

No public regulatory source identifies the commercial supplier of the recombinant human serum albumin used in ERVEBO. The FDA label names the excipient but does not disclose supplier or grade information.[1]

How strong is the ERVEBO patent estate?

The core ERVEBO patent estate is stronger than the excipient estate because the biological construct and production platform are more difficult to design around than the listed formulation ingredients.

Core platform protection

The relevant patent families generally cover:

• Recombinant VSV vectors expressing filovirus glycoproteins.
• VSV vectors with modified or deleted native glycoprotein genes.
• Ebola vaccine compositions.
• Methods of inducing immunity against Zaire ebolavirus.
• Production and recovery of replication-competent or attenuated recombinant VSV.
• Stabilized vaccine preparations and storage conditions.

The technology originated through work involving the Public Health Agency of Canada, the National Microbiology Laboratory, the U.S. government, NewLink Genetics, and Merck. NewLink licensed rights to Merck in 2014, and Merck obtained broader commercial rights to develop and market the vaccine.[2]

Patent strength depends on jurisdiction, claim scope, terminal disclaimers, prosecution history, maintenance payments, and remaining term. The commercial estate should be assessed family by family rather than by counting publications. A large publication count does not necessarily indicate blocking protection.

Excipient-specific strength

Excipient claims are usually narrower and more vulnerable to design-around strategies. A claim limited to recombinant human serum albumin, tromethamine, sodium chloride, and a defined viral concentration could potentially be avoided through:

• A different protein stabilizer.
• A nonprotein excipient system.
• A different buffer.
• A lyophilized or spray-dried presentation.
• A different pH or osmolality range.
• A separate container or freeze-drying process.

The strongest formulation claims would combine composition and performance limitations, such as retained infectivity after defined storage excursions. Such claims are more difficult to invalidate or design around if supported by comparative stability data.

When does ERVEBO lose exclusivity?

ERVEBO received FDA approval on December 19, 2019, under biologics license application 125690.[1] The Biologics Price Competition and Innovation Act provides 12 years of reference-product data exclusivity for a new biological product, subject to statutory qualifications. On that basis, the primary U.S. data-exclusivity period runs to December 2031.

Exclusivity or protection	Timing	Commercial effect
FDA approval	December 19, 2019	Start of U.S. commercial authorization
BPCIA reference-product data exclusivity	Generally through December 2031	Blocks FDA approval of a biosimilar during the data-exclusivity period
Patent rights	Family-specific	May extend beyond or expire before 2031
Pediatric exclusivity	No generally identified ERVEBO extension	No six-month extension included in the base timeline
Orphan-drug exclusivity	Not the principal U.S. protection described for ERVEBO	Ebola prevention is not treated here as a conventional small-molecule orphan product

Patent expiration dates must be determined from the individual U.S. patent families, including patent-term adjustment, patent-term extension, terminal disclaimers, and maintenance status. The December 2031 date is a statutory biologics exclusivity benchmark, not a confirmed freedom-to-launch date.

What is the Orange Book status of ERVEBO?

ERVEBO is not an Orange Book small-molecule product. It is licensed as a biologic under a BLA, so the central U.S. regulatory framework is the Public Health Service Act and the Purple Book rather than an ANDA-based Orange Book listing.[3]

This has several consequences:

• A generic manufacturer cannot file an ANDA for ERVEBO.
• A conventional Paragraph IV challenge is not the normal pathway.
• A competing manufacturer would need to pursue a biologics pathway, likely requiring a 351(a) BLA for a distinct vaccine or a 351(k) biosimilar application if the product qualifies.
• Regulatory interchangeability is a separate issue from patent clearance.
• Patent disputes may occur under the BPCIA framework or through conventional patent litigation, depending on the product and applicant strategy.

No FDA-approved ERVEBO biosimilar is identified in the FDA’s public biologics resources as of the cited regulatory record.[3]

Which companies could challenge ERVEBO?

The competitive threat is more likely to come from alternative Ebola vaccines than from an identical excipient-copying product.

Potential challenger categories include:

Alternative Ebola vaccine developers

Companies and public-sector developers may pursue vaccines based on:

• Adenoviral vectors.
• Modified vaccinia Ankara vectors.
• Protein subunits.
• DNA or RNA platforms.
• Alternative VSV constructs.
• Multivalent filovirus vaccines.

An alternative platform can avoid direct copying of the ERVEBO recombinant VSV construct while competing for the same government procurement contracts.

Biosimilar or follow-on manufacturers

A follow-on manufacturer would face technical obstacles beyond patent clearance:

• Demonstrating comparability of viral-vector identity and potency.
• Reproducing critical quality attributes.
• Establishing manufacturing consistency.
• Demonstrating stability across frozen and thawed states.
• Generating clinical or immunogenicity data acceptable to FDA.
• Qualifying specialized containment and viral-vector manufacturing capacity.

The commercial incentive for a direct follow-on product is limited by the small, episodic, procurement-driven market.

What formulation patents could create commercial value?

The most valuable formulation patents would address deployment constraints rather than simply claim the existing excipient list.

Thermostable formulations

The highest-value opportunity is a vaccine that remains potent for longer periods at 2°C to 8°C or controlled room temperature. A thermostable ERVEBO-type formulation could reduce:

• Ultra-low-temperature freezer requirements.
• Dry-ice shipments.
• Regional stockpile operating costs.
• Vaccine wastage during outbreak response.
• Dependence on specialized vaccination sites.

A patent could cover a stabilizer combination, pH range, drying process, residual moisture, container closure, or defined potency retention after temperature exposure.

Lyophilized or dried presentations

A lyophilized presentation could improve transport and storage, but it would require a reconstitution step and could alter viral recovery, dose uniformity, and field workflow. The drying cycle itself may create protectable process IP.

Potential excipient classes include:

• Sugars and polyols.
• Amino acids.
• Protein stabilizers.
• Surfactants.
• Phosphate, histidine, or other buffers.
• Antioxidants or metal-ion control agents.

Any new system would need to preserve infectivity without increasing aggregation, residual moisture, or reconstitution time.

Multidose and low-waste presentations

ERVEBO’s single-dose format supports sterility and operational simplicity but can increase packaging and wastage. A multidose presentation could lower per-dose cost in mass vaccination campaigns. It would require a validated preservative or aseptic strategy, plus data addressing repeated vial access and dose withdrawal.

A preservative could be difficult to implement because the agent must not reduce live-vector potency. A preservative-free multidose container with validated in-use stability may be more commercially attractive than adding a conventional antimicrobial.

Alternative container systems

Container-closure technology can support patent protection and commercial differentiation. Relevant approaches include:

• Low-binding vial surfaces.
• Prefilled syringes.
• Dual-chamber devices.
• Polymer containers with improved extractables profiles.
• Integrated reconstitution and administration systems.

These products could have value even if the vaccine composition remains unchanged.

What are the commercial opportunities for excipient suppliers?

The market is concentrated but strategically valuable. Excipient suppliers can pursue four routes.

Recombinant human serum albumin

This is the most directly relevant high-value excipient. Suppliers can compete on:

• Regulatory history in vaccines and biologics.
• Lot consistency.
• Global manufacturing capacity.
• Low endotoxin and bioburden profiles.
• Documentation for viral safety and adventitious-agent control.
• Supply continuity during outbreak demand.

A supplier with an established biologics-grade albumin platform has a stronger position than a commodity albumin producer.

Stabilizer screening and formulation services

Contract development organizations can screen excipient systems against live or pseudotyped VSV vectors. Commercial value lies in identifying formulations that retain potency after:

• Freeze-thaw cycles.
• Shipping excursions.
• Long-term frozen storage.
• Short-term refrigerated storage.
• Reconstitution and in-use periods.

The resulting data may support licensing, formulation patents, or a next-generation vaccine product.

Cold-chain reduction

The strongest economic case is lower total cost of ownership. For governments and international agencies, the relevant metric is not excipient price per vial. It is delivered cost per usable dose, including:

• Ultra-low-temperature equipment.
• Dry ice.
• Specialized transport.
• Inventory loss.
• Field freezer capacity.
• Wasted opened or damaged vials.

A formulation that costs more per vial but materially reduces cold-chain losses could win procurement preference.

Platform licensing

An excipient company could license a stabilizer system to Merck or to a future Ebola-vaccine developer. Licensing structures could include:

• Upfront payment for formulation rights.
• Milestone payments tied to clinical or regulatory progress.
• Per-dose royalties.
• Nonexclusive rights across filovirus vaccines.
• Field-of-use restrictions covering public-health procurement.

How does ERVEBO compare with competing Ebola vaccines?

ERVEBO has a direct commercial advantage from regulatory approval, public-health use, and demonstrated deployment experience. Its principal weakness is the severe storage requirement.

Factor	ERVEBO	Alternative vaccine opportunity
Platform	Recombinant VSV	Adenovirus, MVA, protein, RNA, or other platforms
U.S. status	FDA-approved BLA	Product-specific
Storage	-80°C to -60°C under U.S. labeling	May be less demanding, depending on platform
Presentation	Single-dose vial	Potential for multidose, prefilled, or dried formats
Market	Government and outbreak procurement	Same procurement pool
Direct generic risk	Low	Not applicable
Formulation opportunity	Thermal stability and field presentation	Platform-dependent
Manufacturing barrier	Live viral-vector process and containment	Varies by technology

The principal competitive battlefield is procurement performance: speed of deployment, usable-dose yield, storage burden, price, and evidence of protection.

What is the revenue exposure for Merck?

Merck does not generally disclose ERVEBO revenue as a separate line item in its consolidated public reporting. Revenue is therefore difficult to isolate from public company filings. The product’s commercial profile is shaped by public-sector tenders, outbreak response, stockpiling, and international procurement rather than a conventional chronic-care prescription market.

Revenue exposure is concentrated in:

• Government advance purchases.
• International health-agency procurement.
• Outbreak-related orders.
• Strategic reserves.
• Periodic vaccination campaigns.

This creates irregular demand and weakens the incentive for multiple private manufacturers to enter solely through excipient substitution.

What generic launch risks exist for ERVEBO?

A conventional generic launch is not the principal risk. The more credible risks are:

1. An alternative Ebola vaccine with less demanding storage.
2. A competing VSV or viral-vector product with comparable efficacy.
3. A government procurement decision favoring a lower delivered cost.
4. A follow-on biologic supported by a differentiated manufacturing process.
5. A next-generation formulation that reduces wastage or permits refrigerated storage.

The most durable commercial protection is likely to come from the combination of regulatory approval, manufacturing know-how, field-use data, procurement relationships, and platform patents.

Key Takeaways

• ERVEBO uses recombinant human serum albumin, tromethamine, sodium chloride, and Water for Injection.
• Its central technical weakness is the -80°C to -60°C storage requirement.
• The core patent value is concentrated in the recombinant VSV-Ebola construct and manufacturing platform, not necessarily in the named excipients.
• A Paragraph IV generic challenge is not the normal pathway because ERVEBO is a BLA biologic.
• BPCIA data exclusivity generally runs to December 2031 from the 2019 FDA approval.
• The most attractive excipient opportunity is a formulation that preserves viral infectivity under refrigerated or controlled-room-temperature storage.
• Commercial demand is procurement-driven, irregular, and dominated by governments and international health agencies.
• Direct excipient substitution is unlikely to create a large market unless it enables a differentiated ERVEBO-compatible presentation or a competing vaccine.

FAQs

Can recombinant human serum albumin be replaced in an ERVEBO-type vaccine?

Potentially, but replacement would require formulation, stability, potency, safety, and regulatory studies. A substitute must protect the live viral vector without impairing infectivity or increasing aggregation.

Does ERVEBO require an excipient patent license?

Not necessarily. Use of albumin, tromethamine, sodium chloride, and water is not by itself evidence of patent infringement. A license may be required for the recombinant VSV construct, production process, or a claimed stabilized formulation.

Could a thermostable ERVEBO formulation receive separate patent protection?

Yes. Patentable subject matter could include a novel excipient combination, drying process, container system, storage condition, or performance-defined formulation, provided the claims satisfy novelty and non-obviousness requirements.

Is ERVEBO eligible for an ANDA generic?

No. ERVEBO is a biologic vaccine licensed under a BLA. A conventional ANDA and Paragraph IV certification are not the standard approval route.

Which excipient has the highest strategic value in ERVEBO?

Recombinant human serum albumin has the highest strategic value among the listed excipients because it is a biologics-grade stabilizer with supplier qualification, quality, and supply-continuity implications.

References

1. U.S. Food and Drug Administration. (2019). ERVEBO prescribing information.
2. Merck & Co., Inc. (2014). Merck to acquire NewLink Genetics’ Ebola vaccine candidate rights.
3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
4. European Medicines Agency. (2020). Ervebo: EPAR product information.
5. World Health Organization. (2019). Prequalification of Ervebo Ebola vaccine.